Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia

Ibrutinib, an oral covalent inhibitor of Bruton’s tyrosine kinase, is an effective therapy for patients with chronic lymphocytic leukemia (CLL). To determine whether rituximab provides added benefit to ibrutinib, we conducted a randomized single-center trial of ibrutinib vs ibrutinib plus rituximab....

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood
Autori principali: Burger, Jan A., Sivina, Mariela, Jain, Nitin, Kim, Ekaterina, Kadia, Tapan, Estrov, Zeev, Nogueras-Gonzalez, Graciela M., Huang, Xuelin, Jorgensen, Jeffrey, Li, Jianling, Cheng, Mei, Clow, Fong, Ohanian, Maro, Andreeff, Michael, Mathew, Thomas, Thompson, Philip, Kantarjian, Hagop, O’Brien, Susan, Wierda, William G., Ferrajoli, Alessandra, Keating, Michael J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2019
Soggetti:
Plenary Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6405333/
https://ncbi.nlm.nih.gov/pubmed/30530801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-10-879429
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi